OccuLogix RHEO
This article was originally published in The Gray Sheet
Executive Summary
Firm reacquires its North American patent and trademark rights to non-ophthalmic indications for the therapeutic apheresis (TA) product from Rheogenx Biosciences March 29. In exchange, OccuLogix will provide marketing support to Rheogenx subsidiary PhereSys Therapeutics after RHEO's PMA garners FDA approval, expected by mid-2006, for the treatment of "dry" age-related macular degeneration (1"The Gray Sheet" Aug. 23, 2004, p. 8). PhereSys, which plans to become the preferred mobile TA provider of RHEO, also will receive special pricing for OccuLogix pumps and disposable treatment kits related to the device...